Alexander Spira, MD, PhD, Virginia Cancer Specialists, Fairfax, Virginia, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.

Transcript:

Hi, I’m Dr Alex Spira with Virginia Cancer Specialists and I'm going to talk today about the CHRYSALIS study. This is a subset of this study, which was a multifaceted study but specifically data being presented at the World Conference on Lung Cancer this year is regarding the MET Exon 14 skipping [METex14] patients.

As we know, amivantamab is a bispecific monoclonal that hits both MET and EGFR and a lot of data has already been presented specifically for EGFR and the drug is approved in the United States for EGFR exon 20. There's also a MET component to it, so it's strongly believed that it would hit patients who have overactivation of MET, specifically the exon 14 skipping mutation. This cohort I'm going to talk today about is specifically for this MET exon 14 skipping mutation and it was either in patients that were naïve, so did not want to take any of the currently approved meds that are approved for MET such as capmatinib or tepotinib, or a separate group of patients who progressed on the oral [tyrosine kinase inhibitors] TKIs and are looking for another option.

This was a standard clinical trial and patients were dosed according to the current label with amivantamab. In this study, it was found that treatment-naïve patients, so patients that didn’t receive any MET inhibitor in the past, had a 56% response rate and 46% of patients responded who did not receive any prior MET inhibitor. Most notably, 19% of patients who had previously received a MET inhibitor, most commonly tepotinib or capmatinib, also had a response. The duration of response was found to be about 11.2 months. Most importantly, there was a very high clinical benefit rate in treatment-naïve patients of 88% and 66% in patients with prior MET inhibitors. As expected, the most common treatment related adverse events, which have been seen before in patients treated with amivantamab, were infusion-related reaction, paronychia but overall was a very well tolerated drug.

In conclusion, what was found by this abstract is that the MET component of amivantamab makes MET a viable target, specifically looking at the exon 14-skipping patients. As expected, it works in treatment- naïve patients, but also works in a very important subset of relapsed/refractory patients, possibly giving these patients a new option in the future. More data will be coming hopefully with some larger clinical trials, but again very promising results thus far.

Source:

Leighl N, Cho BC, Hiret S, et al. Amivantamab in patients with advanced NSCLC and MET exon 14 skipping mutation: Results from the CHRYSALIS study. Presented at the 2023 World Conference on Lung Cancer; September 9-12, 2023; Singapore. Abstract OA21.04